Efficacy of LAMA Added to ICS in Treatment of Asthma
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the superiority of the glycopyrrolate bromide (CHF
5259 pMDI) versus placebo on top of QVAR® pMDI, in terms of lung functions parameters, as
well as to assess its safety.